idarubicin has been researched along with methylprednisolone in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 10 (66.67) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amiot, L; Caulet-Maugendre, S; Diebold, J; Drénou, B; Fardel, O; Fauchet, R; Lamy, T; Le Prisé, PY; Sasportes, M | 1 |
| Arun, B; Azumi, N; Berberian, B; Frankel, SR; Freter, C; Luksenburg, H | 1 |
| Kulkarni, S; Mainwaring, PN; Powles, RL; Raje, N; Ramiah, V; Sumpter, K; Treleaven, J | 1 |
| Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
| Alpay, R; Disel, U; Paydas, S; Tuncer, I; Yavuz, S | 1 |
| Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U | 1 |
| Hara, T; Kitagawa, J; Moriwaki, H; Oyama, M; Tsurumi, H | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
1 review(s) available for idarubicin and methylprednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for idarubicin and methylprednisolone
| Article | Year |
|---|---|
Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Humans; Idarubicin; Methylprednisolone; Middle Aged; Multiple Myeloma; Remission Induction; Salvage Therapy; Thrombocytopenia; Treatment Failure; Vincristine | 1999 |
13 other study(ies) available for idarubicin and methylprednisolone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; CD3 Complex; CD56 Antigen; Cell Nucleus; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Female; Femoral Neoplasms; Herpesvirus 4, Human; Humans; Idarubicin; Immunophenotyping; Killer Cells, Natural; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Pelvic Neoplasms; Prednisone; Quinine; Vincristine | 1997 |
Sweet's syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cytokines; Glucocorticoids; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Methylprednisolone; Middle Aged; Neutrophils; Remission Induction; Sweet Syndrome; Tretinoin | 1998 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Methylprednisolone; Neutropenia; Recombinant Proteins; Recurrence; Sweet Syndrome; Vidarabine | 2006 |
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Drug Evaluation; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Topotecan; Treatment Outcome; Vidarabine; Vinblastine | 2005 |
Pure erythroid leukemia with hemophagocytosis.
Topics: Antineoplastic Agents; Bone Marrow; Cytarabine; Fatal Outcome; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Lymphohistiocytosis, Hemophagocytic; Male; Methylprednisolone; Middle Aged | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |